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ABSTRACT
There is a long history of research into body fluid biomarkers in neurodegenerative and neuroin-
flammatory diseases. However, only a few biomarkers in CSF are being used in clinical practice.
One of the most critical factors in CSF biomarker research is the inadequate powering of studies
because of the lack of sufficient samples that can be obtained in single-center studies. Therefore,
collaboration between investigators is needed to establish large biobanks of well-defined sam-
ples. Standardized protocols for biobanking are a prerequisite to ensure that the statistical power
gained by increasing the numbers of CSF samples is not compromised by preanalytical factors.
Here, a consensus report on recommendations for CSF collection and biobanking is presented,
formed by the BioMS-eu network for CSF biomarker research in multiple sclerosis. We focus on
CSF collection procedures, preanalytical factors, and high-quality clinical and paraclinical infor-
mation. The biobanking protocols are applicable for CSF biobanks for research targeting any
neurologic disease. Neurology® 2009;73:1914–1922
GLOSSARY
CIS  clinically isolated syndrome; EDSS  Expanded Disability Status Scale; IgG  immunoglobulin G; MALDI-TOF 
matrix-assisted laser desorption/ionization time-of-flight; MS  multiple sclerosis; MSFC  Multiple Sclerosis Functional
Composite; SPMS secondary progressive multiple sclerosis.
There is a long history to the search for body fluid biomarkers in neurodegenerative and neuroin-
flammatory diseases, such asmultiple sclerosis (MS).CSFhasmajor advantages in the studyof neurologic
conditions, although sampling CSF is more invasive than sampling blood or urine.1 Because of its close
proximity to the CNS, the CSFmaymore accurately reflect ongoing pathology of the brain, spinal cord,
andmeninges, and thereforemay provide important and novel information.
Currently, the most frequently used CSF biomarker in MS is the detection of oligoclonal
immunoglobulin G (IgG) bands or quantitative intrathecal IgG synthesis. Despite extensive
research efforts, no other markers have been adopted into clinical practice in MS. Reviews on
the state-of-the-art of biomarker research in MS have shown that the majority of studies are
underpowered.2,3 One of the most critical is the lack of sufficient CSF samples that can be
obtained by a single research center. Therefore, collaboration between investigators is needed.
WHY IS STANDARDIZATION OF CSF COLLECTION PROTOCOLS NEEDED? Standardized collection
protocols should be established to ensure that the statistical power gained by large numbers of samples is not
compromised by preanalytical factors. Furthermore, standardization of collection protocols allows investiga-
tors to replicate studies with samples that match the initial pilot data.
Here, we provide protocols for the standardized collection, biobanking, and exchange of CSF samples. This is a
consensus protocol obtained during meetings of the European network for biomarkers in MS, BioMS-eu, held in
London in March 2007. Large differences were present between collection protocols (figure and table 1). In the
discussions, we have sought a balance between practicality and scientific rationale. Particular attention has been
focused on preanalytic procedures, because errors in the collection, storage, and exchange of biofluids account for
60% of total laboratory errors.4 Last, for optimal CSF research in MS, high-quality clinical and paraclinical data
such as MRI are also needed. Such data will have great importance for the estimation of the prognostic value of a
candidate marker.
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We would like to stress that researchers should ad-
here to these protocols for optimal collaboration in the
field of CSF biomarker research. We suggest using ta-
bles 2 and 3 as a checklist for CSF biomarker research
and recommend that future studies of CSF biomarker
take these issues into account. In discovery-based bio-
marker research, all these items should be considered
carefully before initiating a study. Although some pro-
cedures may not be possible in everyday clinical practice
and less stringent requirements may suffice for specific
research questions, careful documentation of these is-
sues is crucial to facilitate retrieval of appropriate sam-
ples dictated by specific study aims.
Importantly, the procedures for withdrawal and
storage of CSF (table 2) are broadly applicable for
any neurologic disease.
PROCEDURE FOR CSF COLLECTION Item 1: Volume
of withdrawal of at least 12 mL. The CSF volume taken
can influence the concentration of biomarkers. Most
Figure Results of inventory of collection procedures among 14 European centers with CSF biobanks for
multiple sclerosis research in 2006
(A) Other body fluids that are collected simultaneously with CSF. (B) Storage temperature of CSF and serum. (C) Average
volume of CSF that is collected per patient per CSF withdrawal. Bars indicate the average and range of volume per center.
(D) Time delay between CSF withdrawal, spinning, and storage in the freezer. Bars indicate the average and range of time
per center. EDTA ethylenediaminetetraacetic acid; PBMC peripheral blood mononuclear cell.
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molecules and cell numbers have a rostrocaudal con-
centration gradient.5,6 If a small volume is taken, the
CSF will reflect the composition of the lumbar dural
sac, whereas large volumes may reflect the rostral spi-
nal or even ventricular CSF. Therefore, if biomarker
concentrations in a sample from a puncture of 2 mL
are compared with that in a puncture of 15 mL, this
can lead to erroneous results. Also, collecting differ-
ent portions of the CSF for biobanking (e.g., initial
and final volumes of the puncture) may introduce
errors. Thus, a standard volume of CSF should be
collected during lumbar puncture; the first 2 mL can
be used for basic CSF analysis (item 33), and the
remainder of the sample should be pooled before be-
ing divided into aliquot parts. At least, the procedure
must be recorded. The volume of collected CSF does
not correlate with the risk of post–lumbar puncture
headache.7,8
Item 2: Location of puncture vertebral body L3–L5.
Usually, diagnostic CSF is obtained by lumbar punc-
ture. Because of the increasing gradient in protein
concentration from ventricular to lumbar CSF,9 the
site of CSF withdrawal must be recorded. When CSF
is taken from other locations, such as the cervical
cisterns or the lateral ventricles (e.g., ventricular
drainage), this should be documented.
Item 3: Removal of bloody CSF samples. A traumatic
tap causing blood contamination of CSF occurs in
approximately 14% to 20% of standard lumbar
punctures.10 For biomarkers that have high serum
concentrations, such as coagulation factors, blood
contamination can lead to false-positive results. In
addition, blood proteins lead to suppressed matrix-
assisted laser desorption/ionization time-of-flight
(MALDI-TOF)/MS proteomics patterns in CSF.
This suppression by blood proteins is, however,
highly reduced after removal of the blood cells by
centrifugation before initial freezing.11,12 Recording
of erythrocyte count is essential to select CSF sam-
ples appropriate for these measurements. CSF sam-
ples with an erythrocyte count above 500/L should
not be used for biomarker studies.
Item 4: Use of atraumatic needle (Sprotte or Whitacre
needle). There is no evidence that the type of lum-
bar puncture needle influences biomarker concen-
trations. However, atraumatic needles are best
tolerated by patients and are associated with a
lower risk for post–lumbar puncture headache,
i.e., approximately 12% for a needle size of 20–22
gauge compared with approximately 70% for a
needle size of 16–19 gauge.13,14
Item 5: Use of polypropylene collection tubes. There are
several reports showing that the type of collection tube
influences biomarker outcomes, e.g., total tau proteins
and amyloid- peptides.15 Therefore, standardization is
important. We propose to use polypropylene tubes,
with their low protein binding potential, for collecting
CSF. No additives should be used. Glass tubes should
be avoided because of safety reasons for personnel.
Item 6: Time of day of withdrawal. For biomarkers
that are influenced by circadian rhythms, time of
withdrawal is important.16 Because it is often diffi-
cult to accomplish standardization of withdrawal
time in everyday clinical practice, documentation is
necessary to select the appropriate samples to mini-
mize the effect of this variable.
Items 7 and 8: Serum, plasma, and DNA linked to the CSF
sample. It is important to collect matched serum and/or
plasma samples for evaluation of CSF biomarkers be-
cause the concentration of the marker in blood often
influences that in CSF.1 Further, serum/plasma pairs
are essential to study the intrathecal origin of a biomar-
ker and its CNS specificity. Furthermore, the presence
of CNS markers in serum/plasma may aid in disease
monitoring. Vacuum tubes that use ethylenediami-
netetraacetic acid (in dried format) are preferred over
those that use citrate (in solution), because if tubes con-
taining a standard volume of citrate are filled incom-
pletely, the final biomarker concentration is diluted
artificially. Depending on the type of biomarkers and
methods of study, we recommend collecting both se-
rum and plasma17; for some methods, plasma is pre-
ferred over serum and vice versa. Serum/plasma samples
should not be hemolytic.
Last, DNA collection expands the possibilities for
studying the phenotypes and genotypes within indi-
viduals. A protocol for storage and handling of DNA
can be found in appendix e-1 on the Neurology®
Web site at www.neurology.org.
Item 9: Storage at room temperature until spinning
and dividing into aliquots. For CSF, there are no data
available yet that support a preference for leaving the
Table 1 Results of inventory on collection protocols among 14multiple
sclerosis biomarker research centers
Procedure for CSFwithdrawal Previous status among European CSF centers
Type of needle 71% atraumatic, 21% traumatic, 8% both
Time of day of withdrawal (important for
markers that are sensitive to circadian
rhythm)
71% no specific day/time of withdrawal, 29% in the
afternoon only
Temperature until storage 57% at room temperature, 43% at 4°C
Type of tube 50% Sarstedt, 29% Eppendorf, 21% other
Dividing into aliquots Range 0.2–2 mL
Surveillance of freezers Present at 93% of the centers
Several freezers to split the samples
(backup)
Present at 14% of the centers
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samples at room temperature or at 4°C until pro-
cessing. For serum/plasma, it is more crucial. To
avoid platelet activation,18 serum/plasma samples
should be kept at room temperature before centrif-
ugation. Therefore, processing at room tempera-
ture for both serum/plasma and CSF, including
during and after spinning, is suitable for most
studies. Relatively few systematic studies have
been performed on this issue. We would recom-
mend exploratory studies to define the effect of
temperature on specific biomarkers.
Item 10: Standardized spinning conditions. We pro-
pose to adhere to a standardized spinning protocol of
400 g for 10 minutes at room temperature when frag-
ile cells need to be preserved for RNA of cell isola-
tion, and otherwise at 2,000 g. For serum, we
propose to spin at 2,000 g for 10 minutes at room
temperature. Standardization of spinning tempera-
ture and speed may be important for some biomark-
ers, although no studies have addressed these specific
preanalytical variables for CSF. For plasma and se-
rum, temperature of processing is known to be criti-
cal for specific biomarkers.19 After centrifugation, the
supernatant must be divided into aliquots and stored
immediately. If this is not done, the processing time
should be documented.
Item 11: Standardization of time delay between with-
drawal, spinning, and freezing. Studies of the effects
of preanalytical variables by MALDI-TOF/MS pro-
teomics (proteins/peptides 20 kD) have shown
that the time between sampling and storage is more
crucial for specific serum proteins or peptides than
for CSF.11,12,20 For CSF, it was observed that process-
ing within 2 hours does not lead to artifactual re-
sults.11,12 For serum, it was observed that small
differences in processing time (approximately 10–30
minutes) can result in different proteomics spectra.17
Some biomarkers, such as antibodies or specific cyto-
kines, are not very sensitive to sampling and storage
conditions.21 For practical reasons and in view of the
standard of 30- to 60-minute clotting time for se-
rum, we recommend a time delay of 1.5 hours (30
minutes) for both matrices. When CSF cells are to be
preserved, processing as soon as possible is advised
because cell numbers decrease quickly. However, in
most of the centers, processing of the body fluid sam-
ples within 1 hour is not common practice. There-
fore, documentation of time of withdrawal and
storage is required to select uniform samples. For
newly discovered biomarkers, these preanalytical
variables should be evaluated.
Item 12: Use of small polypropylene tubes for ali-
quots. Because of the same rationale as for CSF with-
drawal (item 5), we recommend that polypropylene
tubes should be used for division into aliquots and
storage. Furthermore, vials with screw caps should be
used for a secure sealing.
Table 2 Consensus-based recommendations for CSFwithdrawal procedure
Item Procedure Ideal situation
1 Preferred volume At least 12 mL; first 1–2 mL for basic CSF
assessment (see issue 33); last 10 mL for
biobanking
Record volume taken and fraction used for
biobanking
2 Location Vertebral body L3–L5
3 If bloody Do not process further
Criteria for bloody: more than 500 red blood
cells/L
Record number of blood cells in diagnostic
samples
4 Type of needle Atraumatic
5 Type of collection tube Polypropylene tubes, screw cap, volume 1–2 mL
6 Time of day of withdrawal and
storage
Preferably standardized within each center,
allowing for intercenter differences in local
logistics
Record date and time of collection
7 Other body fluids that should be
collected simultaneously
Serum
8 Other body fluids that should be
collected simultaneously
Plasma: EDTA (preferred over citrate)
9 Storage temperature until
freezing
Room temperature before, during, and after
spinning
10 Spinning conditions Serum: 2,000g, 10 min at room temperature
CSF: 400g, 10 min at room temperature/2,000g
if no cells are to be preserved
11 Time delay between withdrawal
and spinning and freezing
Optimal for CSF: 1–2 h
Optimal for serum: 30–60 min
Thus doing both body fluids simultaneously,
ideally within 1 h
After spinning, samples must be divided into
aliquots and frozen immediately for storage at
80°C
12 Type of tube for aliquots Small polypropylene tubes (1–2 mL) with screw
caps; record manufacturer
13 Aliquots A minimum of 2 aliquots is recommended; the
advised research sample volume of 10 mL should
be enough for10 aliquots
14 Volume of aliquots Minimum 0.1 mL; depending on total volume of
tube: 0.2, 0.5, and 1 mL; preferably, the tubes are
filled up to 75%
15 Coding Unique codes; freezing-proof labels; ideally
barcodes to facilitate searching, to aid in blinding
the analysis and to protect the privacy of patients
16 Freezing temperature 80°C
17 Additional items on sample
collection protocols that must
be recorded
Location of samples
18 Additional items on sample
collection protocols that must
be recorded
Surveillance of freezers
19 Additional items on sample
collection protocols that must
be recorded
Splitting of samples over 2 or more freezers
EDTA ethylenediaminetetraacetic acid.
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Item 13: Aliquots. Freeze/thaw cycles can influence
biomarker concentrations.22 For example, 1-time
freezing of CSF samples can lead to a highly signifi-
cant loss of amyloid-, which is decreased a further
20% after 3 more thawing cycles.23,24 By contrast, no
effects on CSF proteome profiles obtained by
MALDI-TOF/MS have been observed after up to 4
freeze/thaw cycles.12
In principle, repeated freezing/thawing of samples
should be avoided, because data addressing this topic
are available for only a few biomarkers and the re-
sponse to freeze/thaw cycles of new biomarkers is not
known. Thus, splitting the pooled sample into mul-
tiple small aliquots is optimal, and eventual freeze/
thaw cycles should be recorded.
Item 14: Volumes of aliquots of 0.2, 0.5, and 1 mL.
Small aliquot volumes are optimal to avoid freezing/
thawing and to avoid waste of CSF. The proposed
tube sizes are 0.25, 0.5, and 1 mL. Tubes should be
filled up to 75% to prevent freeze-drying within the
tube, which will affect the concentration of biomark-
ers, although it may only be a problem if the seal of
the cryogenic tubes are not airtight. This issue has
not been formally studied and is not referred to in
related standard operating procedures.25
Item 15: Coding and use of freezing-proof labels. Unique
codes are necessary to track samples and pair with clini-
cal data. Ideally, bar codes should be used to facilitate
searching, to aid in blinding the analysis, and to protect
the privacy of patients. It is important to have center-
unique codes, to track data retrospectively. Labels must
be water and frost (80°C) resistant.
Item 16: Freezing temperature of 80°C. Proteins
may not be stable at 20°C for years. In one study,
the effect of storing CSF at 20°C and 80°C on
cystatin C, an abundant CSF protein, was investi-
gated. Cleavage of this protein occurred in all sam-
ples stored at 20°C but not in samples stored at
80°C.26 Apart from the cystatin C truncation,
changes in the low molecular weight polypeptide
profile due to CSF sample storage at 20°C for 3
months seemed to be minimal.11,12 Oligoclonal
bands in CSF may be recovered after several years of
storage at 20°C, indicating a high stability of im-
munoglobulins.27 No data are available showing the
benefit of storage of CSF or serum in liquid nitrogen.
Because this is expensive and not practical for CSF
biobanking, there is no basis yet to recommend stor-
age in liquid nitrogen.
Taking these data together, we recommend that
samples are stored at80°C to ensure long-term sta-
bility of biomarkers.
ADDITIONAL ITEMS OF SAMPLE COLLECTION
PROTOCOLS THAT MUST BE RECORDED IN
MS BIOMARKER RESEARCH Item 17: Location of
samples. To enable easy tracking and fast relocation
of samples, storage information should include
freezer location, freezer identification, and sample lo-
cation within the freezer.
Items 18 and 19: Surveillance of freezers and splitting
of samples. Freezers should be alarm controlled, and
a sample rescue plan should be established and docu-
mented. All freezers must be registered in a freezer
log file. Ideally, daily temperature logs should be
available for all freezers. Aliquots of samples should
Table 3 Consensus-based recommendations for information requirements in
databases of patients with multiple sclerosis
Item The following characteristics should be recorded:
Basic demographics
20 Date of birth (age if date of birth is not available)
21 Gender
22 Ethnicity
Outcomemeasurements
Clinical characteristics
23 Clinical subtype at time of sampling according to McDonald criteria32
24 Date of first symptoms
25 Date of diagnosis according to McDonald criteria, date of first and second
events
26 Date of conversion from RRMS to SPMS (if possible)
27 EDSS at sampling; if possible, MSFC and other validated functional outcome
measures at sampling
28 EDSS and other functional scores (e.g., MSFC) at follow-up (i.e., the patients
should be followed up); include the date of measurement
29 Relapses
Number and, if possible, dates of relapses in the 2 y before collection of sample
Time between the start of last relapse and collection of sample
Relapse at the time of sampling according to Schumacher criteria (1 increase
in EDSS 24 h on stable background for at least 30 days) 41
30 Number and, if possible, dates of relapses at each year of follow-up
31 Glucocorticoid therapies, at sampling and year before sampling
32 Use of other drugs, at sampling and year before sampling
33 Basic CSF analysis (CSF cell count, differential cytology, erythrocyte count,
oligoclonal IgG bands [which is at least 2 bands by definition], albumin ratio,
total protein [if albumin is not measured], and IgG index)
Record the methods of routine analysis
MRI characteristics
34 MRI scan of brain and spinal cord; record date
35 Number and volume of Gd-contrast enhancing MRI lesions, T1 and T2 lesion
volumes, and brain/spinal cord atrophy, when available
36 Follow-up MRI scans, if possible
General database requirements
37 The data in the CSF database should be in English and use standardized
international units
RRMS  relapsing-remitting multiple sclerosis; SPMS  secondary progressive multiple
sclerosis; EDSSExpanded Disability Status Scale; MSFCMultiple Sclerosis Functional
Composite; IgG immunoglobulin G; Gd gadolinium.
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be distributed among different freezers. Ideally, an
empty backup freezer should be available.
INFORMATION REQUIREMENT IN DATABASE IN
THE CONTEXT OF MS Items 20 and 21: Basic demo-
graphics, such as age and gender. Information on the age
at sampling is needed to allow comparability to age-
matched reference values, because many proteins
show age-dependent changes, e.g., albumin or IgG.28
Ideally, date of birth and date of sampling are re-
corded (table 3). Gender must be provided because
of variability of markers influenced by hormones.
Item 22: Ethnicity. Reference ranges of biomarkers
can be influenced by the genetic status.29 For exam-
ple, a recent study observed a higher IgG index in
African Americans than in Caucasians, unrelated to
socioeconomic status.30 Criteria for race and ethnic-
ity are available via the Web site of the NIH.31
STANDARDIZATION OF OUTCOME MEASURE-
MENTS IN MS Items 23–26: Clinical subtype at time of
sampling, date of onset, and date of diagnosis. A goal of
biomarker research is to identify surrogate endpoints
for relevant disease characteristics such as clinical
subtype, disease duration, disease activity, and pro-
gression. Therefore, it is crucial that diagnosis is
made according to standard criteria32,33 and that the
correct disease subtype at sampling is recorded. The
date of first and second events should also be re-
corded to define the date of conversion from
clinically isolated syndrome (CIS) to clinically defi-
nite MS.32,33
The following clinical subtypes (stages) of MS
are commonly differentiated: CIS, relapsing-
remitting MS, relapsing secondary progressive MS
(SPMS), nonrelapsing SPMS, primary progressive
MS, and progressive relapsing MS.34 The time
point of conversion to SPMS may be helpful to
distinguish between slow and rapidly progressive
MS or to develop biomarkers to predict conver-
sion to the SPMS phase.
Item 27: Expanded Disability Status Scale and functional
scores at sampling. We recommend using appropriate
and well-validated outcome measures. Although Ex-
panded Disability Status Scale (EDSS) scores and func-
tional scores35 are not linear disease severity scores and
do not necessarily reflect progression rate, inflammatory
activity, and lesion load,36,37 they are important for
stratification purposes and as a measure of severity.
However, it is advised to include other clinical scales
too, such as the Multiple Sclerosis Functional Compos-
ite (MSFC) and its subscores.38,39 The MSFC also ac-
counts for cognitive functioning, which is affected in
30% to 70% of MS patients.40
Item 28: Clinical scores at follow-up. Follow-up EDSS,
functional system scores, and preferably MSFC and its
subscores are helpful to determine disease progression
rate, which is an important clinical endpoint required
for evaluation of candidate biomarkers.
Item 29: Number of relapses in the preceding years
before collection of sample and time between last re-
lapse and lumbar puncture. Numbers of relapses is an
indicator for retrospective clinical activity that may
influence biomarker status. Relapses should be de-
fined according to the Schumacher criteria,41 and the
dates should also be recorded to determine the time
interval between the start of the last relapse and the
time of sampling. It is important to relate number of
relapses to a defined retrospective time window, pref-
erably 2 years, to obtain comparable and reliable data
on annual relapse frequency.
Item 30: Number of relapses at each year of follow-up.
Because annual relapse rates are often used to de-
scribe the clinical activity and most MS therapies
mainly affect the number of relapses, this is an im-
portant target variable for biomarker research.42,43
Ideally, dates of relapses should be recorded, which
allows for studying whether a biomarker predicts
early vs late relapses.
Items 31 and 32: Treatment at sampling and year be-
fore sampling. It is well known that commonly used
drugs for treatment of MS, including immunomodu-
latory agents and methylprednisolone for treatment
or prevention of relapses, have an influence on ex-
pression of biomarkers.44,45 Therefore, type and dura-
tion of treatment, also not related to MS therapy,
should be documented in detail, preferably begin-
ning at least 1 year before CSF collection.
Item 33: Basic CSF analysis (protein, cell counts,
erythrocytes, and so on). To enable stratification of
patients according to their CSF findings and to eval-
uate suitability of samples for further analysis, results
of basic CSF analysis should be recorded. Primarily,
the CSF profile serves for exclusion of other diseases.
In addition, quantitative changes of immunologic
markers are likely to occur, depending on disease
stage, relapse activity, and medication. Inflammatory
processes may influence the blood-CSF barrier func-
tion and thereby biomarker concentrations.1
Oligoclonal IgG bands are important to test the
value of a new diagnostic biomarker. The sensitivity
of oligoclonal IgG bands is strongly dependent on
the method used. We strongly recommend isoelec-
tric focusing followed by immunoblotting and stain-
ing for IgG.46,47 Preferably, the methods of all routine
diagnostic procedures, including oligoclonal band-
ing, should be documented.
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Items 34 and 35: MRI characteristics. This informa-
tion should contain the following items: whether a
brain and/or spinal cord MRI has been performed,
the date the study was performed, and where it was
performed (to access the source data if required).
Preferably, the data set should be available for later
analysis. It is questionable whether the number of
lesions and total lesion load are reliably recorded
with routine diagnostic studies, but these are valuable
parameters for estimating disease activity. There is
great variation between different imaging centers re-
garding which routine sequences are obtained (axial
vs sagittal, T2 vs proton density vs fluid-attenuated
inversion recovery techniques, slice thickness, and so
on). A valuable and reliable parameter to collect is
the number of gadolinium enhancing lesions, be-
cause the presence of gadolinium enhancing lesions
reflects the inflammatory activity at the time of the
scan and ideally also of the CSF or blood collection.
In the context of studies on biomarkers for neurode-
generation and neuroprotection in MS, information
regarding brain atrophy is valuable, although several
outcome measures of atrophy exist in various centers.
A common MRI protocol would be desirable.48,49
Item 36: Longitudinal MRI scans. Longitudinal MRI
scans would be desirable to monitor disease progres-
sion, and they may be possible in some centers.
However, because of the lack of using standardized
MRI protocols in routine investigations, regular
follow-up MRIs cannot be recommended at present.
Item 37: Data in the CSF database in English. The
mask on the database screen could be in the local
language, but the underlying files will need to be in
English. It is strongly suggested to use a commer-
cially available program, if not a common database
for networks such as BioMS-eu. The database should
also adhere to standardized international units.
ETHICAL ISSUES For collaboration in Biomarker
research, the presence of good ethical protocols that
comply with national and international ethical and
other legal regulations is of utmost importance.
Most, if not all, centers already have a good ethical
protocol for CSF biobanking and biomarker re-
search. The most important issues are that the proto-
col allows exchange of (coded or pseudoanonymized)
samples and relevant patient information, and pa-
tient consent. To address the needs of investigators,
samples should initially be pseudoanonymized, i.e.,
stored with a code that can be linked to subject iden-
tifiers so that clinical details could be updated after
the sample has been collected. However, when sam-
ples are extracted from the biobank for the purposes
of research, they should be released as anonymized
samples, i.e., stripped of their link with personal
identifiers. This is to protect the privacy of individu-
als participating in research.
Researchers may have to give notice of new re-
search projects to their ethical office and make mate-
rial transfer agreements. Because rules differ among
centers and countries, it is the responsibility of the
research centers to adapt their procedures according
to local rules.
CONCLUDING REMARKS The lists provided in ta-
ble 2 can be used as an easy checklist for CSF bio-
banking for any CNS disease, applicable during
setup of the procedures and also as a checklist for
recording sample characteristics. It is expected that
these standardizations will pave the way for large
biomarker studies and fruitful collaborations. Ulti-
mately, these endeavors are to arrive at validated
biomarker assays for diagnosis, prognosis, and treat-
ment of CNS diseases and a potential to elucidate
relevant disease mechanisms.
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